Smart Insulin Pens with Built-In Calculators Show Promise for Better Blood Sugar Control
A new study compares two types of connected insulin pens and finds that pens with integrated bolus calculators may help adults on multiple daily injections achieve better glycemic control than tracking-only pens.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Smart insulin pens with built-in bolus calculators reduced HbA1c more effectively than pens that only track insulin doses
- The study included 120 adults with type 1 and type 2 diabetes using multiple daily injections and continuous glucose monitors
- Both groups used continuous glucose monitors, suggesting the added benefit comes from the calculator feature itself
- This is a 12-week trial, so longer-term effects remain unknown
What Are Smart Insulin Pens?
Connected insulin pens are devices that track your insulin doses and can communicate with your glucose monitoring system. A newer version, called smart insulin pens, goes a step further: they include a built-in bolus calculator that helps you figure out how much insulin to take based on your blood sugar and carbohydrate intake.
The question researchers wanted to answer was simple: does having that calculator built into the pen actually help you manage your diabetes better than just using a pen that tracks your doses?
How the Study Was Designed
Researchers at nine medical centers in South Korea recruited 120 adults aged 19 to 74 years old with either type 1 or type 2 diabetes who were using multiple daily injections. About 44% had type 1 diabetes. All participants used continuous glucose monitors to track their blood sugar throughout the day.
Participants were randomly assigned to use either a smart insulin pen with a bolus calculator or a tracking-only connected pen for 12 weeks. The main question was: which group would see a greater decrease in their HbA1c, the measure of average blood sugar control over three months?
What the Results Showed
Of the 120 participants enrolled, 116 completed the study and were included in the analysis. The smart insulin pen group showed a greater decrease in HbA1c compared to the tracking-only group. The study also looked at continuous glucose monitor metrics and insulin dosing behavior, though specific numerical results for these secondary measures are not detailed in the abstract.
Both groups started with an average HbA1c of about 8.5%, indicating room for improvement in blood sugar control.
What This Means for People Using Insulin
This study suggests that the calculator feature in smart insulin pens may provide real value beyond just tracking your doses. However, it's important to remember this is one 12-week trial. Whether the benefits last longer than three months, or how these pens compare to other decision-support tools like smartphone apps, would require additional research.
The results apply to adults using multiple daily injections—both type 1 and type 2 diabetes. If you're interested in smart insulin pens, talk with your healthcare provider about whether this technology might fit your diabetes management plan.
Key Study Details
This was a randomized controlled trial published in Diabetologia, meaning participants were randomly assigned to groups and the study was designed to minimize bias. It was conducted across nine centers in South Korea and lasted 12 weeks. All participants used continuous glucose monitors alongside their assigned insulin pen type, which allowed researchers to evaluate the complete picture of glucose management.
Evidence label
Source: Diabetologia. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryDiagnosis & Early DetectionA Simple Blood Test May Help Doctors Assess How Severe Your DKA IsPubMed indexed literature
- Research summaryDiagnosis & Early DetectionA New Approach to Finding Type 1 Diabetes Early: Testing During Routine CheckupsPubMed indexed literature
- Research summaryDiagnosis & Early DetectionSingle Autoantibody: What It Means When Your Child Tests Positive for One Type 1 MarkerPubMed indexed literature
- Research summaryDiagnosis & Early DetectionKetosis-Prone Type 2 Diabetes: New Clues to an Immune Mix-UpPubMed indexed literature
- Research summaryDiagnosis & Early DetectionWhy Screening for Type 1 Diabetes Before Symptoms MatterPubMed indexed literature
- Research summaryDiagnosis & Early DetectionTesting for Type 1 Before Symptoms Appear: What a Real-World Pilot LearnedPubMed indexed literature